Noveko International Inc. Announces Results for the Third Quarter Ended March 31, 2009



    
       Demand for Antimicrobial Face Masks Up as of the Fourth Quarter

    -------------------------------------------------------------------------
    EKO/TSX
    

    MONTREAL, May 15 /CNW Telbec/ - Noveko International Inc. ("the Company")
today announces the financial results for its third quarter ended March 31,
2009.
    "Despite a 10.5% revenue growth over the third quarter of the previous
year, our quarterly results remain below our expectations. However, we look
forward to promising developments in light of the initiatives we have recently
taken as well as the current context. These initiatives include the
distribution agreement with Aerosys Technologies for our filters, the one with
Garda Security Group for our antimicrobial face masks and AZURO(TM)
disinfectants, and all the other progress achieved in marketing our various
products," indicated André Leroux, Chairman of the Board and Chief Executive
Officer of the Company

    
    Financial Highlights

    For the third quarter and first nine months of the current fiscal year,
respectively, and in comparison with the corresponding periods of the previous
year:

    - Consolidated revenues up by 10.5% and 35.5%
    - Loss before amortization, financial expenses and income taxes -
      including stock-based compensation - up by $1.8 million and
      $8.0 million
    - Net loss up by $1.9 million and $10.2 million

    Demand and Production of Antimicrobial Face Masks Up

    "As you know, the threat of an A (H1N1) flu virus pandemic has recently
led to a sharp increase in the demand for our Noveko(TM) antimicrobial face
masks and respirators. We believe that the accelerator effect related to the
current situation will also have a positive impact over the longer term on the
marketing of our face masks and AZURO(TM) products," added Alain Bolduc,
President and Chief Operating Officer of the Company.
    The Company confirms it has so far won additional orders for some 7.5
million 3xEZ and 4xEZU antimicrobial surgical masks and 5dEZR and 9dEZR
respirators. These face masks are scheduled to be delivered to different
markets, notably North America, Europe and the Middle East, and will be spread
over the current quarter and the next quarter, as the inventories become
available. In addition, negotiations are underway with respect to several
other orders that could represent additional sales of approximately 18 million
antimicrobial face masks and respirators.
    In order to meet this demand on an orderly basis and considering its
limited inventories, the Company has taken the necessary steps to increase its
production of face masks. First, the Company has started to assemble the
inventories of the various face mask components it already had. Using these
different components, the Company expects, at the current production rate, to
be able to gradually produce some 7 million face masks in the coming months.
However, the Company is in talks with various potential suppliers to increase
the pace of assembling the face mask materials. Secondly, the Company has also
taken the necessary measures to begin producing approximately 20 million
additional face masks. The Company plans to complete their production in
upcoming quarters.

    Analysis of Operating Results

    Selected Consolidated Quarterly Information
    (in thousands of $, except per-share amounts) (unaudited)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                  Three Months                Nine Months
                              2009(1)       2008          2009(1)       2008

    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Revenues                 3,934         3,560        13,779        10,171
    Gross margin             1,844         1,693         5,565         4,249
    Loss before
     amortization, financial
     expenses and income
     taxes(2)               (5,502)       (3,664)      (16,376)       (8,397)
    Net loss                (5,708)       (3,844)      (19,188)       (9,002)
    Comprehensive loss      (7,062)       (2,999)      (19,525)       (8,092)
    Loss per Class A share
     (basic and diluted)     (0.09)        (0.07)        (0.29)        (0.17)
    Weighted average number
     of Class A shares
     outstanding
     (in thousands)         66,999        55,281        66,472        53,563
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Balance Sheet Data
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                          March 31,      June 30,
                              2009          2008
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    Total assets            63,213        62,858
    Shareholders' equity    49,560        49,773
    Total interest-bearing
     debt(3)                 7,426         7,860
    Cash, cash equivalents,
     cash in trust and
     short-term investments  8,345        25,386
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
    (1) The consolidated financial statements for the three-month and
        nine-month periods ended March 31, 2009 include the financial
        statements of the Company and its wholly-owned subsidiaries
        Noveko Inc. ("Noveko"), S.A.S. ECM ("ECM"), Bolduc Leroux Inc.
        ("BLI"), Laboratoire SyMa Inc., Groupe Conseils Micron-Air Inc.
        ("Micron-Air"), Magnum Pharmaceutics Inc. ("Magnum"), Noveko Trading
        2008 LLC ("Noveko Trading"), Noveko Taiwan Co., Ltd., SARL Noveko
        Algérie ("Noveko Algérie"), Unitam International Management
        Corporation Inc. ("Unitam"), Purer Life Technology Co., Ltd. ("Purer
        Life") and U-Bond Inc.
    (2) Including stock-based compensation of 3,031, 2,470, 9,309 and
        4,849 for the respective periods of 2009 and 2008.
    (3) Including long-term debt and its current portion, bank advances and
        bank loans, as well as convertible debentures.

    For the third quarter, consolidated revenues amounted to $3.9 million, up
by 10.5% over the corresponding quarter of the previous year. This increase is
due primarily to the contribution of the new subsidiaries Noveko Algérie,
Micron-Air, Magnum and Purer Life for the full quarter. For the first nine
months of the current fiscal year, consolidated revenues amounted to $13.8
million, up by $3.6 million or 35.5% over the nine-month period ended March
31, 2008. This increase is primarily due to the aforementioned factors.
    For the third quarter and the first nine months of the current fiscal
year, selling and administrative expenses amounted to $3.9 million and $12.0
million respectively, up by 37.4% and 55.4% over the corresponding periods of
the previous year. These increases were caused by the total payroll and
operating expenses of the subsidiaries acquired in the past quarters in
Canada, Algeria and Taiwan, and the expenses related to the marketing of the
derivative products from the antimicrobial filtration technology.
    Stock-based compensation represented an expense of $3.0 million for the
third quarter and $9.3 million for the first nine months of the current fiscal
year, compared with $2.5 million and $4.8 million respectively for the
corresponding periods of the previous year. Stock options were primarily
granted in connection with the acquisitions completed since the beginning of
the year.
    Considering the aforementioned factors, the loss before amortization,
financial expenses and income taxes amounted to $5.5 million for the third
quarter, up by $1.8 million over the corresponding quarter of the previous
year. For the first nine months, it totaled $16.4 million, an increase of $8.0
million over the corresponding period of the previous year.
    Amortization expenses amounted to $0.6 million for the third quarter and
$1.8 million for the first nine months, up by $0.4 million and $1.1 million
respectively over the corresponding periods of the previous year. These
differences are due primarily to the acquisitions completed since the
beginning of the year. Financial expenses represented a negative amount of
$0.2 million, reflecting a loss on currency contracts of $0.5 million offset
by foreign exchange gains of $0.7 million in the third quarter. For the first
nine months, financial expenses totaled $1.2 million, reflecting a loss on
currency contracts of $2.2 million offset by foreign exchange gains of $1.0
million.
    The net loss amounted to $5.7 million for the third quarter, up by $1.9
million over the corresponding period of the previous year, mainly on account
of the aforementioned factors. Considering a net change in unrealized gains on
translation of financial statements of self-sustaining foreign operations of
$1.4 million - compared with $0.9 million in the third quarter of the previous
year - a net loss of $7.1 million represented the comprehensive loss for the
third quarter, compared with $3.0 million for the corresponding quarter of the
previous year. For the first nine months, the net loss amounted to $19.2
million, up by $10.2 million over the first nine months of the previous year.
Considering a net change in unrealized gains on conversion of financial
statements of self-sustaining foreign operations of $0.3 million, a net loss
of $19.5 million represented the comprehensive loss for the first nine months
of the current fiscal year.
    The loss per Class A share (basic and diluted) amounted to $0.09 on a
weighted average of 66,998,694 outstanding shares for the third quarter,
compared with a loss per share of $0.07 on a weighted average of 55,281,253
shares for the corresponding quarter of the previous year. For the first nine
months, the loss per share (basic and diluted) increased to $0.29 from $0.17
per share for the first nine months of the previous year.

    Third-Quarter Highlights and Subsequent Events

    Proposed sale of BLI - Closing of the transaction is now scheduled for May
31, 2009.
    Preliminary business discussions with Microban International, Ltd. - The
European subsidiary Noveko Trading and Microban International, Ltd. have
engaged in preliminary discussions about a business partnership. No formal
agreement has been entered into thus far, but the parties had identified
several opportunities where such collaboration could potentially be very
attractive.
    Significant breakthrough in the aeronautics field - The Company has
signed, on behalf of some of its subsidiaries, an exclusive distribution
agreement for filters incorporating Noveko's antimicrobial filtration
technology with the French firm Aerosys Technologies. This agreement covers
the marketing of the filters, worldwide, to aircraft manufacturers,
aeronautics maintenance companies and air carriers and, in France, to the
railway, auto manufacturing and defence industries, with certain exceptions.
Aerosys Technologies has already successfully carried out several of the
prerequisite tests to market the filters incorporating Noveko's antimicrobial
filtration technology in the aeronautics niche. Aerosys Technologies plans to
present the new filters incorporating the Noveko(TM) technology at the Paris
Le Bourget International Aeronautics and Space Trade Fair to be held from June
15 to June 21, 2009.
    Noveko Algérie awarded major orders - In April 2009, Noveko Algérie
obtained significant new orders to supply various medical devices to the
National Office of Equipment and Accessories for Handicapped People in
Algeria. The orders are estimated at approximately $1.4 million and the
devices are scheduled to be delivered throughout the calendar year ending
December 31, 2009.
    First deliveries of antimicrobial face masks to Mexico - In April 2009,
the Company made a first delivery of about one million 3xEZ and 4xEZU
antimicrobial face masks to Mexico.
    Distribution agreement with Garda Security Group - In May 2009, the
Company concluded, together with its subsidiary Noveko, a distribution
agreement with Garda Security Group, a subsidiary of Garda World Security
Corporation, covering the Noveko(TM) antimicrobial face masks and Azuro(TM)
antiseptic disinfectants.
    Effectiveness of Noveko(TM) antimicrobial face masks against the Human
Influenza A Virus (H1N1) - On May 12, 2009, the Company announced it had
received the preliminary results of tests conducted by Microbiotest Lab, an
independent laboratory located in Sterling, Virginia, USA, on the Noveko(TM)
antimicrobial masks with respect to the Influenza A Virus (H1N1) similar to
the one responsible for the human swine flu. The preliminary results
demonstrated a bio-efficacy of a Log 3 Reduction over a period of 30 minutes,
specifically the effectiveness of the Company's face masks in inactivating the
Human Influenza A Virus (H1N1) at 99.9%.
    Initiatives for the creation of a Chinese subsidiary - The Company has
taken steps to establish its presence in the Chinese market through a
subsidiary in order to accelerate its business development in China, one of
its target markets.
    FDA certification application process - At the beginning of April 2009,
the Company filed with the FDA the documentation related to the results of the
tests conducted on the Noveko(TM) 3xEz antimicrobial surgical mask
demonstrating a "4 log reduction" bio-efficacy against bacteria. The FDA
submission assessment process is still underway. The Company remains
optimistic as to obtaining FDA approval.
    Health Canada approval of the Imagyne(TM) ultrasound scanner - In April
2009, ECM was granted Health Canada approval to sell the Imagyne(TM)
ultrasound scanner in healthcare institutions across Canada.
    Installation of air filters - The Company recently proceeded with the
first installations of air filters integrating Noveko's antimicrobial
technology in commercial buildings in the Greater Montreal Area. Performance
tests are currently in progress.
    Appointment of a Vice-Chairman to the Board of Directors - Pursuant to the
adoption of new corporate governance guidelines, the Company's Board of
Directors has appointed Jean-Guy Parent, Independent Director, as
Vice-Chairman of the Board.

    Profile

    Noveko International Inc. offers innovative solutions in the environmental
and medical fields worldwide. Through its subsidiaries, the Company
specializes primarily in the following business segments: the development,
manufacturing and marketing of derivative products from its patented
antimicrobial filtration technology, including air filters, surgical masks and
respirators, along with other products with antimicrobial properties such as
AZURO(TM) antiseptic disinfectants - and the development, manufacturing and
marketing of medical equipment, primarily portable real-time ultrasound
scanners for use in human and veterinary medicine.

    Certain statements set forth in this press release constitute
forward-looking statements. In some cases, these statements are identified by
the use of terms such as "may", "could", "might", "intend", "should",
"expect", "project", "plan", "believe", "estimate" or other comparable
variants. These statements are based on the information available at the time
they are written, on assumptions made by management and on the expectations of
management, acting in good faith, regarding future events, including those
relating to economic conditions, fluctuations in exchange rates and operating
expenses, and the absence of unusual events entailing supplementary
expenditures. Although management considers these assumptions and expectations
reasonable based on the information available at the time they are written,
they could prove inaccurate. Forward-looking statements are also subject, by
their very nature, to known and unknown risks and uncertainties such as those
related to the industry, acquisitions, labor relations, credit, key officers,
supply and product liability. The actual results of Noveko International Inc.
could differ materially from those indicated or underlying these
forward-looking statements. The reader is therefore recommended not to unduly
rely on these forward-looking statements. Forward-looking statements do not
reflect the potential impact of special items, any business combination or any
other transaction that may be announced or occur subsequent to the date
hereof. The Company undertakes no obligation to update or revise the
forward-looking statements to account for new events or new circumstances,
except where provided for by applicable legislation.

    -------------------------------------------------------------------------
    The Management's Report, consolidated financial statements and
    accompanying notes for the quarter ended March 31, 2009 will be filed on
    SEDAR (www.sedar.com).
    -------------------------------------------------------------------------


    Consolidated balance sheets

    As at March 31, 2009 and June 30, 2008

    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                                      March 31       June 30
                                                          2009          2008
    -------------------------------------------------------------------------
                                                    (unaudited)     (audited)
    Assets
    Current assets:
      Cash and cash equivalents                   $    291,101  $ 11,594,335
      Deposit for acquisition                           74,340     1,274,625
      Short-term investments                         7,979,355    12,516,884
      Accounts receivable                            5,866,089     5,092,191
      Inventories                                    8,597,983     5,868,045
      Prepaid expenses                                 523,894       820,119
    -------------------------------------------------------------------------
                                                    23,332,762    37,166,199

    Fixed assets                                     8,682,621     7,206,885
    Intangible assets                               10,475,502     2,572,372
    Other assets                                     1,128,493     1,442,283
    Future income taxes                                477,850       762,311
    Goodwill                                        19,116,068    13,708,240
    -------------------------------------------------------------------------
                                                  $ 63,213,296  $ 62,858,290
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Liabilities and shareholders' equity

    Current liabilities:
      Bank advances                               $  1,297,540  $  1,112,665
      Bank loan                                              -       561,435
      Accounts payable and accrued liabilities       3,750,824     4,318,727
      Current portion of long-term debt                933,819       636,116
    -------------------------------------------------------------------------
                                                     5,982,183     6,628,943

    Long-term debt                                   3,431,138     3,086,827
    Secured convertible debentures                   1,763,990     2,462,909
    Future income taxes                              2,476,469       906,464

    Shareholders' equity:
      Capital stock                                 80,680,736    70,084,061
      Portion of secured convertible debentures
       included in equity                              372,473       611,537
      Warrants                                               -        85,983
      Contributed surplus                           17,014,626     7,967,778
      Accumulated other comprehensive income            10,376       347,359
      Deficit                                      (48,518,695)  (29,323,571)
    -------------------------------------------------------------------------
                                                    49,559,516    49,773,147
    -------------------------------------------------------------------------
                                                  $ 63,213,296  $ 62,858,290
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------


    Consolidated statements of operations

    Three and nine month periods ended March 31, 2009 and 2008
    (unaudited)

    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                 Three months                 Nine months
                              2009          2008          2009          2008
    -------------------------------------------------------------------------

    Revenues          $  3,933,804  $  3,559,944  $ 13,779,447  $ 10,171,027

    Cost of sales        2,089,909     1,866,842     8,214,765     5,921,581
    -------------------------------------------------------------------------

                         1,843,895     1,693,102     5,564,682     4,249,446

    Operating
     expenses:
      Administrative
       and selling
       expenses          3,915,492     2,849,181    12,013,048     7,732,258
      Stock-based
       compensation      3,030,931     2,470,334     9,308,848     4,848,740
      Research and
       development         422,493        53,257     1,096,550       333,002
      Research and
       development
       tax credits         (23,324)      (15,216)     (477,665)     (267,803)
    -------------------------------------------------------------------------

                         7,345,592     5,357,556    21,940,781    12,646,197
    -------------------------------------------------------------------------
    Loss before
     amortization,
     financial
     expenses and
     income taxes       (5,501,697)   (3,664,454)  (16,376,099)   (8,396,751)

     Amortization          620,162       264,982     1,831,176       756,088
    Financial expenses    (225,462)      (50,727)    1,178,853       (11,505)
    -------------------------------------------------------------------------

                           394,700       214,255     3,010,029       744,583
    -------------------------------------------------------------------------

    Loss before income
     taxes              (5,896,397)   (3,878,709)  (19,386,128)   (9,141,334)

    Income taxes:
      Current
       (recovered)        (166,514)       43,511      (175,360)       45,569
      Future               (21,948)      (78,161)      (22,401)     (185,364)
    -------------------------------------------------------------------------

                          (188,462)      (34,650)     (197,761)     (139,795)
    -------------------------------------------------------------------------

    Net loss          $ (5,707,935) $ (3,844,059) $(19,188,367) $ (9,001,539)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Basic and diluted
     earnings per
     share            $      (0.09) $      (0.07) $      (0.29) $      (0.17)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Weighted average
     number of
     outstanding
     shares basic
     and diluted        66,998,694    55,281,253    66,471,880    53,562,687
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------


    Consolidated statements of comprehensive loss

    Three and nine month periods ended March 31, 2009 and 2008
    (unaudited)

    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                 Three months                 Nine months
                              2009          2008          2009          2008
    -------------------------------------------------------------------------

    Net loss          $ (5,707,935) $ (3,844,059) $(19,188,367) $ (9,001,539)

    Other
     comprehensive
     loss, net of
     income taxes:

      Change in
       unrealized
       gains (losses)
       on translation
       of financial
       statements of
       self-sustaining
       foreign
       operations       (1,354,233)      845,329      (336,983)      909,413
    -------------------------------------------------------------------------

    Comprehensive
     loss             $ (7,062,168) $ (2,998,730) $(19,525,350) $ (8,092,126)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------


    Consolidated statements of deficit and contributed surplus

    Nine month periods ended March 31, 2009 and 2008
    (unaudited)

    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                                      March 31      March 31
                                                          2009          2008
    -------------------------------------------------------------------------

    DEFICIT

    Deficit, beginning of period                  $(29,323,571) $(12,672,254)

    Restatement related to the new accounting
     policies                                           49,243         3,161
    -------------------------------------------------------------------------

    Restated balance                               (29,274,328)  (12,669,093)

    Net loss                                       (19,188,367)   (9,001,539)

    Share issuance fees                                (56,000)      (25,090)
    -------------------------------------------------------------------------
    Deficit, end of period                        $(48,518,695) $(21,695,722)
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    CONTRIBUTED SURPLUS

    Contributed surplus, beginning of period      $  7,967,778  $  1,325,504

    Fair value of stock options granted              9,308,848     4,848,740

    Fair value of stock options exercised             (262,000)     (619,119)

    -------------------------------------------------------------------------
    Contributed surplus, end of period            $ 17,014,626  $  5,555,125
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------


    Consolidated statements of cash flows

    Three and nine month periods ended March 31, 2009 and 2008
    (unaudited)

    -------------------------------------------------------------------------
    -------------------------------------------------------------------------
                                 Three months                 Nine months
                              2009          2008          2009          2008
    -------------------------------------------------------------------------

    Cash flows from
     operating
     activities:
      Net loss        $ (5,707,935) $ (3,844,059) $(19,188,367) $ (9,001,539)
      Adjustments
       for :
        Future
         income
         taxes             (21,948)      (78,161)      (22,401)     (185,364)
        Accreted
         interest on
         secured
         convertible
         debentures         64,635       100,248       201,945       361,622
        Stock-based
         compensation    3,030,931     2,470,334     9,308,848     4,848,740
        Amortization
         (note 5a))        620,162       264,982     1,831,176       756,088
        Loss (gain)
         on fair
         value of
         short-term
         investments          (433)       79,197        (3,254)       47,606
        Unrealised
         loss (gain)
         on currency
         contracts         472,420             -       (76,885)            -
        Gain on
         disposal of
         fixed assets       (1,954)            -        (9,185)            -
        Foreign
         exchange
         loss (gain)        (5,688)           70        (6,233)        1,905
    -------------------------------------------------------------------------

                        (1,549,810)   (1,007,389)   (7,964,356)   (3,170,942)

    Net change in
     non-cash working
     capital              (967,567)   (1,286,977)   (5,848,946)   (3,464,063)
    -------------------------------------------------------------------------
                        (2,517,377)   (2,294,366)  (13,813,302)   (6,635,005)

    Cash flows from
     financing
     activities :
      Net changes in
       bank advances       (97,493)      439,580       184,875       718,177
      Increase in
       bank loan            11 760       180,600             -       324,800
      Repayment of
       bank loan                 -             -      (584,850)            -
      Increase in
       long-term debt      117,516       211,172       177,516       211,172
      Principal
       repayment on
       long-term debt     (198,381)     (206,928)     (534,989)     (733,791)
      Interest paid
       on secured
       convertible
       debentures          (39,747)      (64,832)     (125,911)     (240,979)
      Proceeds of
       Class A shares
       and warrants
       issued less
       related expenses     30,000     2,739,101     3,956,775     6,121,218
    -------------------------------------------------------------------------
                          (116,345)    3,298,693     3,073,416     6,400,677

    Cash flows from
     investing
     activities:
      Business
       acquisition,
       including cash
       acquired and
       overdraft
       assumed             (29,686)            -    (5,936,483)     (525,403)
      Acquisition of
       fixed assets       (180,430)     (364,602)     (685,763)   (1,772,879)
      Proceeds from
       disposal of
       fixed assets         23,000             -        31,859             -
      Government
       assistance
       related to
       acquisition of
       fixed assets              -             -             -        47,500
      Acquisition of
       intangible
       assets              (56,652)      (10,368)     (332,693)      (20,118)
      Proceeds from
       disposal of
       short-term
       investments       4,421,842    18,418,650    62,177,235    38,678,214
      Acquisition of
       short-term
       investments      (1,297,584)  (19,197,644)  (55,603,116)  (38,180,203)
      Acquisition of
       other assets              -       (49,505)            -      (326,152)
      Deposit for
       acquisition             380             -        (1,755)            -
      Deferred
       development
       costs               (87,913)      (77,507)     (259,130)     (242,456)
    -------------------------------------------------------------------------
                         2,792,957    (1,280,976)     (609,846)   (2,341,497)

    Foreign exchange
     loss (gain) on
     cash in foreign
     currencies             (7,603)       89,219        46,498        89,941
    -------------------------------------------------------------------------

    Net change in
     cash and cash
     equivalents           151,632      (187,430)  (11,303,234)   (2,485,884)
    Cash and cash
     equivalents,
     beginning of
     period                139,469       370,040    11,594,335     2,668,494
    -------------------------------------------------------------------------

    Cash and cash
     equivalents, end
     of period        $    291,101  $    182,610  $    291,101  $    182,610
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Cash flows related to operating activities include interest paid for
    $435,789 ($361,222 in 2008) and income taxes received for $104,300 (paid
    for $157,103 in 2008).
    




For further information:

For further information: Chantal Vennat, Director, Investor Relations
and Corporate Communications, Noveko International Inc., (514) 875-0606,
http://www.noveko.com

Organization Profile

Noveko International Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890